Life Sciences Opportunities in India & China: From Innovation to Commercialization
30 September 2009
China and India are emerging as major players in the life sciences industry. Both countries have a wealth of top talent as well as rapidly-improving resources for the industry. Both countries also constitute important current and potential markets for drugs, devices and diagnostics, and are also projected to be major sources of innovation in the not-too-distant future. This panel will explore the significant opportunities in China and India, in terms not only of expanding operations to both countries, but also in terms of working with innovative companies that originate from China and India.
Moderator:
- David A. Charapp, Special Counsel, Foley & Lardner LLP
Panelists:
- Stephen A. Bent, Partner, Foley & Lardner LLP
- Friedhelm Blobel, Ph.D., President, CEO, Director, SciClone Pharmaceuticals
- Kim Kamdar, Ph.D., Principal at Domain Associates
- Sanjay Shukla, M.D., M.S., Chief Executive Officer, RxMD
Related Insights
22 April 2024
Foley Ignite
AI Regulatory and Legal Issues Today: A Conversation with Natasha Allen
As is the case with most emerging technologies, developments in artificial intelligence are quickly outpacing regulations, and with this comes a variety of important legal considerations.
22 April 2024
Foley Ignite
The Complex Terrain of the Video Game Industry: Challenges and Opportunities
The video game industry is brimming with innovation, competition, and transformative technological advancements.
22 April 2024
Labor & Employment Law Perspectives
Utah Enacts H.B. 55, Impacting the Use of Confidentiality Clauses in Employment Settlement Agreements
On March 13, 2024, Governor Spencer Cox signed House Bill (H.B.) 55 into law, making Utah the latest state to restrict the use of certain nondisclosure and non-disparagement agreements relating to sexual assault or sexual harassment claims.